GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Altimmune Inc (NAS:ALT) » Definitions » Cyclically Adjusted PB Ratio

Altimmune (Altimmune) Cyclically Adjusted PB Ratio : 0.11 (As of Apr. 28, 2024)


View and export this data going back to 2005. Start your Free Trial

What is Altimmune Cyclically Adjusted PB Ratio?

As of today (2024-04-28), Altimmune's current share price is $7.26. Altimmune's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 was $67.84. Altimmune's Cyclically Adjusted PB Ratio for today is 0.11.

The historical rank and industry rank for Altimmune's Cyclically Adjusted PB Ratio or its related term are showing as below:

ALT' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.02   Med: 0.15   Max: 8.06
Current: 0.11

During the past years, Altimmune's highest Cyclically Adjusted PB Ratio was 8.06. The lowest was 0.02. And the median was 0.15.

ALT's Cyclically Adjusted PB Ratio is ranked better than
87.99% of 641 companies
in the Biotechnology industry
Industry Median: 1.72 vs ALT: 0.11

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Altimmune's adjusted book value per share data for the three months ended in Dec. 2023 was $2.746. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $67.84 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Altimmune Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Altimmune's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Altimmune Cyclically Adjusted PB Ratio Chart

Altimmune Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.03 0.14 0.12 0.22 0.17

Altimmune Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.22 0.06 0.05 0.04 0.17

Competitive Comparison of Altimmune's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Altimmune's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Altimmune's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Altimmune's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Altimmune's Cyclically Adjusted PB Ratio falls into.



Altimmune Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Altimmune's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=7.26/67.84
=0.11

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Altimmune's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Altimmune's adjusted Book Value per Share data for the three months ended in Dec. 2023 was:

Adj_Book=Book Value per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=2.746/129.4194*129.4194
=2.746

Current CPI (Dec. 2023) = 129.4194.

Altimmune Quarterly Data

Book Value per Share CPI Adj_Book
201403 46.446 99.695 60.294
201406 58.704 100.560 75.552
201409 87.308 100.428 112.512
201412 86.194 99.070 112.599
201503 94.341 99.621 122.560
201506 86.068 100.684 110.632
201509 82.375 100.392 106.193
201512 77.582 99.792 100.615
201603 72.743 100.470 93.703
201606 112.299 101.688 142.924
201609 615.975 101.861 782.626
201612 142.640 101.863 181.228
201703 78.695 102.862 99.013
201706 147.769 103.349 185.044
201709 93.744 104.136 116.505
201712 65.285 104.011 81.233
201803 54.660 105.290 67.187
201806 28.752 106.317 35.000
201809 22.996 106.507 27.943
201812 5.322 105.998 6.498
201903 4.410 107.251 5.322
201906 4.180 108.070 5.006
201909 3.220 108.329 3.847
201912 2.973 108.420 3.549
202003 2.728 108.902 3.242
202006 2.995 108.767 3.564
202009 6.038 109.815 7.116
202012 6.081 109.897 7.161
202103 6.442 111.754 7.460
202106 6.079 114.631 6.863
202109 5.271 115.734 5.894
202112 4.858 117.630 5.345
202203 4.277 121.301 4.563
202206 4.195 125.017 4.343
202209 4.171 125.227 4.311
202212 3.766 125.222 3.892
202303 3.403 127.348 3.458
202306 3.185 128.729 3.202
202309 2.845 129.860 2.835
202312 2.746 129.419 2.746

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Altimmune  (NAS:ALT) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Altimmune Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Altimmune's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Altimmune (Altimmune) Business Description

Industry
Traded in Other Exchanges
Address
910 Clopper Road, Suite 201S, Gaithersburg, MD, USA, 20878
Altimmune Inc is engaged on developing treatments for obesity and liver diseases. The Company's pipeline includes next generation peptide therapeutics for obesity and non-alcoholic steatohepatitis (NASH) (for both, pemvidutide, formerly known as ALT-801), and for chronic hepatitis B (HepTcell). The Company is managed and operates as a single business focused on the research and development of treatments for various diseases and disorders, and vaccines.
Executives
David Drutz director 8601 SIX FORKS ROAD, SUITE 160, RALEIGH NC 27615
Richard I Eisenstadt officer: Chief Financial Officer 4819 EMPEROR BOULEVARD, SUITE 400, DURHAM NC 27703
Catherine A. Sohn director C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2
Matthew Scott Harris officer: Chief Medical Officer C/O ALTIMMUNE, INC., 910 CLOPPER ROAD, SUITE 201S, GAITHERSBURG MD 20878
Raymond M Jordt officer: Chief Business Officer ALTIMMUNE, INC., 910 CLOPPER ROAD, SUITE 201S, GAITHERSBURG MD 20878
Wayne Pisano director C/O PROVENTION BIO, INC., P.O. BOX 666, OLDWICK NJ 08858
Vipin K Garg director, officer: President and CEO 4819 EMPEROR BOULEVARD, SUITE 400, DURHAM NC 27703
John Gill director C/O PHARMATHENE, INC, ONE PARK PLACE, SUITE 450, ANNAPOLIS MD 21401
M Scot Roberts officer: Chief Scientific Officer 910 CLOPPER ROAD, SUITE 201S, GAITHERSBURG MD 20878
Diane Jorkasky director 60 MANOR AVENUE, WELLESLEY MA 02482
Philip Hodges director 19 FIRSTFIELD RD., SUITE 200, GAITHERSBURG MD 20878
Vhcp Management Iii, Llc 10 percent owner 7 BRYANT PARK, 23RD FLOOR, NEW YORK NY 10018
Venrock Healthcare Capital Partners Ii, L.p. 10 percent owner 7 BRYANT PARK, 23RD FLOOR, NEW YORK NY 10018
Venrock Healthcare Capital Partners Iii, L.p. 10 percent owner 530 FIFTH AVENUE, 22ND FLOOR, NEW YORK NY 10036
Vhcp Co-investment Holdings Iii, Llc 10 percent owner 7 BRYANT PARK, 23RD FLOOR, NEW YORK NY 10018